Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of

More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Webinar on Eryaspase in Pancreatic Cancer (September 1, 2021)
Presentation on the lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, featured by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2021.
               Monthly information related to total number of voting rights and shares composing the share capital – September 3 0 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers   LYON, France , Oct. 04, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2018
LYON, France, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Jun 8 - Jun 10, 2022

Jefferies Global Healthcare Conference (New York, USA)

Summary Toggle Jun 23 - Jun 24, 2022

Spring Midcap Event (Paris, France)

Summary Toggle Jun 24, 2022 at 9:00 AM CEST

Shareholders’ Meeting

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top